Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients-Reference-Cited by-同舟云学术

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Published:2017-08 Issue:8 Volume:28 Page:1988-1995
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sanmamed M.F.,Perez-Gracia J.L.,Schalper K.A.,Fusco J.P.,Gonzalez A.,Rodriguez-Ruiz M.E.,Oñate C.,Perez G.,Alfaro C.,Martín-Algarra S.,Andueza M.P.,Gurpide A.,Morgado M.,Wang J.,Bacchiocchi A.,Halaban R.,Kluger H.,Chen L.,Sznol M.,Melero I.

Funder

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/8/1988/24169539/mdx190.pdf

Reference28 articles.

1. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future;Chen;J Clin Invest,2015

2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma;Ansell;N Engl J Med,2015

3. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

4. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

5. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

Cited by 348 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer;Heliyon;2024-09

3. Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge;International Journal of Molecular Sciences;2024-08-31

4. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer;Journal of Experimental Medicine;2024-08-27

5. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma;OncoImmunology;2024-08-26